Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup phase III trial N0147. - Alberts,S.R.; Sargent,D.J.; Smyrk,T.C. (J Clin Oncol, 2010)